Related references
Note: Only part of the references are listed.Clinical significance of homologous recombination deficiency score testing in endometrial Cancer
Jean H. Siedel et al.
GYNECOLOGIC ONCOLOGY (2021)
Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Significance of tumor mutation burden combined with immune infiltrates in the progression and prognosis of ovarian cancer
Fangfang Bi et al.
CANCER CELL INTERNATIONAL (2020)
Mismatch Repair Pathway, Genome Stability and Cancer
Nives Pecina-Slaus et al.
FRONTIERS IN MOLECULAR BIOSCIENCES (2020)
Gynecological Cancers Caused by Deficient Mismatch Repair and Microsatellite Instability
Madhura Deshpande et al.
CANCERS (2020)
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study
U. A. Matulonis et al.
ANNALS OF ONCOLOGY (2019)
Comparison between whole exome sequencing (WES) and single nucleotide polymorphism (SNP)-based tumor mutation burden analysis.
Kirsten Timms et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
Kathleen N. Moore et al.
LANCET ONCOLOGY (2019)
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
A. Gonzalez-Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
R. L. Coleman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
I. Ray-Coquard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forks
Gabriel Balmus et al.
NATURE COMMUNICATIONS (2019)
Harnessing DNA Double-Strand Break Repair for Cancer Treatment
Anika Trenner et al.
FRONTIERS IN ONCOLOGY (2019)
Biomarkers for Homologous Recombination Deficiency in Cancer
Michal M. Hoppe et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Biomarker Assessment of HR Deficiency, Tumor BRCA1/2 Mutations, and CCNE1 Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy
Euan A. Stronach et al.
MOLECULAR CANCER RESEARCH (2018)
Biomarkers for Homologous Recombination Deficiency in Cancer
Michal M. Hoppe et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin plus /- veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC.
Melinda L. Telli et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
Darren R. Hodgson et al.
BRITISH JOURNAL OF CANCER (2018)
Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study
Barbara M. Norquist et al.
CLINICAL CANCER RESEARCH (2018)
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman et al.
LANCET (2017)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Eric Pujade-Lauraine et al.
LANCET ONCOLOGY (2017)
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Aaron M. Goodman et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Evaluation of BRCA1/2 and homologous recombination defects in ovarian cancer and impact on clinical outcomes
Melinda S. Yates et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Elevated tumor mutational burden and prolonged clinical response to anti-PD-L1 antibody in platinum-resistant recurrent ovarian cancer
Christopher B. Morse et al.
GYNECOLOGIC ONCOLOGY REPORTS (2017)
Landscape of Microsatellite Instability Across 39 Cancer Types
Russell Bonneville et al.
JCO PRECISION ONCOLOGY (2017)
BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer
M. Moschetta et al.
ANNALS OF ONCOLOGY (2016)
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
Melinda L. Telli et al.
CLINICAL CANCER RESEARCH (2016)
Homologous recombination deficiency and ovarian cancer
Jonathan A. Ledermann et al.
EUROPEAN JOURNAL OF CANCER (2016)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
M. R. Mirza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
Kyle C. Strickland et al.
ONCOTARGET (2016)
Inherited Mutations in Women With Ovarian Carcinoma
Barbara M. Norquist et al.
JAMA ONCOLOGY (2016)
Development and analytical validation of a 25-gene next generation sequencing panel that includes the BRCA1 and BRCA2 genes to assess hereditary cancer risk
Thaddeus Judkins et al.
BMC CANCER (2015)
Involvement of ATM in homologous recombination after end resection and RAD51 nucleofilament formation
A. Bakr et al.
NUCLEIC ACIDS RESEARCH (2015)
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Panagiotis A. Konstantinopoulos et al.
CANCER DISCOVERY (2015)
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
Jonathan Ledermann et al.
LANCET ONCOLOGY (2014)
Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes
Kirsten M. Timms et al.
BREAST CANCER RESEARCH (2014)
Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer
V. Abkevich et al.
BRITISH JOURNAL OF CANCER (2012)
Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation
Tatiana Popova et al.
CANCER RESEARCH (2012)
Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents
Nicolai J. Birkbak et al.
CANCER DISCOVERY (2012)
Hereditary ovarian cancer: recent molecular insights and their impact on screening strategies
Kara C. Long et al.
CURRENT OPINION IN ONCOLOGY (2011)
The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
Thomas Helleday
MOLECULAR ONCOLOGY (2011)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer
Bryan T. J. Hennessy et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support
Paul A. Harris et al.
JOURNAL OF BIOMEDICAL INFORMATICS (2009)
Systematic Review and Meta-analysis of Ovarian Cancers: Estimation of Microsatellite-High Frequency and Characterization of Mismatch Repair Deficient Tumor Histology
Tuya Pal et al.
CLINICAL CANCER RESEARCH (2008)
The resurgence of platinum-based cancer chemotherapy
Lloyd Kelland
NATURE REVIEWS CANCER (2007)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study
RF Ozols et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: What prognostic factors are important?
JK Chan et al.
OBSTETRICS AND GYNECOLOGY (2003)
Improved survival in women with BRCA-associated ovarian carcinoma
I Cass et al.
CANCER (2003)
Genome maintenance mechanisms for preventing cancer
JHJ Hoeijmakers
NATURE (2001)
Share Paper
